Received Sep 29, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| COVID19 | COVID19 (COVID19 (MODERNA)) | MODERNA | 1 | 024M20A | IM |
Received booster dose (0.25 ml) instead of 3rd primary series dose (0.5 ml).; Hodgkin's lymphoma; This spontaneous case was reported by a consumer and describes the occurrence of HODGKIN'S DISEASE (Hodgkin's lymphoma) in a 75-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 017E21A, 029A21A and 024M20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below. Concurrent medical conditions included Osteoporosis. On 12-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular use) .5 milliliter. On 12-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular use) dosage was changed to .5 milliliter. On 18-Aug-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular use) dosage was changed to .25 milliliter. On 25-Mar-2021, the patient experienced HODGKIN'S DISEASE (Hodgkin's lymphoma) (seriousness criterion medically significant). On 18-Aug-2021, after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced UNDERDOSE (Received booster dose (0.25 ml) instead of 3rd primary series dose (0.5 ml).). At the time of the report, HODGKIN'S DISEASE (Hodgkin's lymphoma) was resolving and UNDERDOSE (Received booster dose (0.25 ml) instead of 3rd primary series dose (0.5 ml).) outcome was unknown. Concomitant drugs were not reported. Treatment details included chemotherapy. The patient stated she was diagnosed with Hodgkin's lymphoma on 25Mar2021. She reported she started chemotherapy treatment in April 2021. Her last chemotherapy treatment was either in June or July 2021. She stated that her cancer went into remission after the chemotherapy treatments. The patient reported she considered herself immunocompromised at the time when she received her Moderna booster dose on 18Aug2021 due to the cancer diagnosis and chemotherapy treatments. The patient stated that the adverse events were not due to any of three doses. This case was linked to MOD-2022-511169 (Patient Link). Most recent FOLLOW-UP information incorporated above includes: On 14-Mar-2022: Upon internal review significant corrections were performed on 29-Aug-2025 after which the case was reassessed and determined to be valid. On 06-Apr-2022: Follow up received information added to I narrative supplement; Reporter's Comments: Hodgkin's lymphoma was assessed as not related to Moderna COVID vaccine due to very short latency. Company causality for underdose is not applicable. The benefit-risk relationship of product is not affected by this report.
Osteoporosis